Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ABVC BioPharma, Inc. - Common Stock (NQ:ABVC)

3.940 +0.590 (+17.61%)
Streaming Delayed Price Updated: 11:27 AM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ABVC BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
FREMONT, CA - (NewMediaWire) - March 19, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS,... 
Via TheNewswire.com
Topics Intellectual Property
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
Via TheNewswire.com
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars
FREMONT, CA - (NewMediaWire) - February 27, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS... 
Via TheNewswire.com
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
The Company holds a U.S. patent for the same treatment 
Via TheNewswire.com
Topics Intellectual Property
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
FREMONT, CA - (NewMediaWire) - February 8, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology,... 
Via TheNewswire.com
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
Via AB Newswire
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
FREMONT, CA - (NewMediaWire) - January 3, 2024 - ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing therapeutic... 
Via NewMediaWire
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC Executes Cooperation Agreement for Strategic Investments
FREMONT, CA - (NewMediaWire) - August 17, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology,... 
Via NewMediaWire
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC Corporate Update and CEO's Letter to Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ABVC Biopharma (NASDAQ: ABVC) Inks Major Licensing Agreement with Xinnovation Therapeutics for ABV-1504 and ABV-1505
Landmark Licensing Deal for ABVC in China's Growing Healthcare Market ABVC Biopharma, Inc. (NASDAQ: ABVC), a pioneer in the development 
Via Spotlight Growth
Topics Intellectual Property
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
FREMONT, CA - (NewMediaWire) - July 31, 2023 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology,... 
Via NewMediaWire
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.